Validation of an anti-α-Gal IgE fluoroenzyme-immunoassay for the screening of patients at risk of severe anaphylaxis to cetuximab, BMC Cancer

Background The link between immediate hypersensitivity reactions (HSR) following the first cetuximab infusion and the IgE sensitization against anti-galactose-α-1,3-galactose (α-Gal) is now well-established. An automated Fluoroenzyme-Immunoassay (FEIA) is available and may facilitate the screening of patients with anti-α-Gal IgE before treatment. Methods This study aimed to evaluate its performances as compared to a previously validated anti-cetuximab IgE ELISA, using 185 samples from two previously studied cohorts. Results Despite 21.1% of discrepancies between the two techniques, FEIA discriminated better positive patients and similarly negative ones with a ≥ 0.525 kUA/L threshold. Sensitivity was 87.5% for both tests, specificity was better for FEIA (96.3% vs ELISA: 82.1%). FEIA had a higher positive likelihood ratio (23.9 vs ELISA: 4.89) and a similar negative likelihood ratio (0.13 vs ELISA: 0.15). In our population, the risk of severe HSR following a positive test was higher with FEIA (56.7% vs ELISA: 19.6%) and similar following a negative test (0.7% vs ELISA: 0.8%). Conclusion Although the predictive value of the IgE screening before cetuximab infusion remains discussed, this automated commercial test can identify high-risk patients and is suitable for routine use in laboratories. It could help avoiding cetuximab-induced HSR by a systematic anti-α-Gal IgE screening before treatment.

PDF) Validation of an anti-α-Gal IgE fluoroenzyme-immunoassay for the screening of patients at risk of severe anaphylaxis to cetuximab

Suppression of IgE-mediated anaphylaxis and food allergy with monovalent anti-FcεRIα mAbs - ScienceDirect

Forest plot and SROC curve. Download Scientific Diagram

Patient characteristics (n = 92)

Gautier Petit's research works Centre Hospitalier Universitaire de Caen, Caen (CHU Caen) and other places

Risk factors associated with hypersensitivity reactions to cetuximab: anti-cetuximab IgE detection as screening test

Frontiers IgE and IgG Antibodies as Regulators of Mast Cell and Basophil Functions in Food Allergy

Frontiers Epithelial cell alarmin cytokines: Frontline mediators of the asthma inflammatory response

Frontiers The History of Carbohydrates in Type I Allergy

The basophil activation test differentiates between patients with alpha-gal syndrome and asymptomatic alpha-gal sensitization - ScienceDirect

Anti-IgE as a mast cell–stabilizing therapeutic agent - ScienceDirect

Hypersensitivity reactions to biologics (part II): classifications and current diagnostic and treatment approaches*

Frontiers Allergen-Specific IgA Antibodies Block IgE-Mediated Activation of Mast Cells and Basophils

Frontiers Beyond IgE—When Do IgE-Crosslinking and Effector Cell Activation Lead to Clinical Anaphylaxis?

Forest plot and SROC curve. Download Scientific Diagram